| 產(chǎn)品名稱 | VMM5A |
|---|---|
| 商品貨號 | B167207 |
| Organism | Homo sapiens, human |
| Tissue | Melanoma, Lymph Node Metastasis |
| Cell Type | Melanocyte |
| Product Format | frozen |
| Morphology | Epithelial-like |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Melanoma, Stage IIIC; malignant |
| Age | 81 |
| Gender | Male |
| Ethnicity | Caucasian |
| Applications | Drug screening Development of targeted therapy Development of combination therapy Tumor vaccine development |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | Derived from tumors taken from tumor-involved lymph nodes from patients at the University of Virginia |
| Clinical Data | Primary Site: Right Posterior Shoulder; Metastatic Site: Lymph Node, Right Neck |
| Antigen Expression | Positives: High VEGF-R2, Low GP100, Tyrosinase, Low MAGE-A1, MMP-1 |
| HLA Typing | A2.1,A1101,B39,B44, BW4,BW6,C7(17)DR7, DR8,DR11,DQ2,DQ7 |
| Comments | NRAS: wt CDKN2A: wt BRAF Mutation: V600E APC Mutation PDGFRA Mutation: D842V PTEN Mutation: R173H more sensitive to BAY43-9006 (BRAF kinase inhibitor) and to rapamycin (mTOR kinase inhibitor), compared to cell lines with wild-type B-Raf |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Volumes are for a T-75 flask; Adjust accordingly
|
| Cryopreservation | Fetal bovine serum, 90%; DMSO, 10% |
| Culture Conditions | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2 ), 5% |
| STR Profile | Amelogenin: X,Y D5S818: 9 D7S820: 9,10 D13S317: 12 D16S539: 12 vWA: 16 TH01: 9.3 TPOX: 8,11 CSF1PO: 11 |
| Sterility Tests | Pass |
| Name of Depositor | Craig L. Slingluff, Jr. M.D. |
| Passage History | Unknown. 2 passages from 2003 frozen cell line stock, but it is not known how long the line was in culture after being established from tumor tissue obtained in 1992. |
| Year of Origin | 1992 |
| References | Slingluff C, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol. Immunother. 48:661-672, 2000. PubMed: 10752474 Molhoek K, et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2. Cancer Res. 68: (11), 2008. PubMed: 18519701 Molhoek K, et al. Comprehensive analysis of RTK activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Res 21(4): 274–284, 2011. PubMed: 21654344 Molhoek K, et al. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J. Trans. Med. 3(39): 2005. PubMed:16255777 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
